You are here:

Bivalirudin 250mg for injection or infusion (Angiox®)

Advice

Following a full submission

Bivalirudin (Angiox) is accepted for restricted use within NHS Scotland as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA) procedures like angioplasty and balloon angioplasty and PTCA with stenting.

It is restricted to patients who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein llb/llla antagonist. In these patients bivalirudin monotherapy may be a suitable alternative. It should not be used as an alternative to unfractionated heparin alone.

Drug Details

Drug Name: Bivalirudin 250mg for injection or infusion (Angiox®)
SMC Drug ID: 156/05
Manufacturer: Nycomed UK Ltd
Indication: Anticoagulant in patients undergoing percutaneous coronary intervention
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Restricted
Date Advice Published: 7 March 2005

Back